Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.